News, reviews and podcasts from annual scientific meetings and symposiums around the world.
Researchers observed encouraging response rates in older or high-risk patients with newly diagnosed acute myeloid…
The chemotherapy-free regimen of ponatinib and blinatumomab achieved high response rates and reduced the need…
The latest results of a Phase II study evaluating the addition of venetoclax to the…
New four-year follow-up results from the Phase 3 GLOW study (Abstract #93), were announced during…
The targeted drug zanubrutinib showed superior efficacy with fewer side effects than ibrutinib in the…
The immunotherapy blinatumomab was found to improve overall survival for patients with no measurable residual…
The Phase 3 MAIA study’s updated analyses reported progression-free survival, minimal residual disease negativity, overall…
During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13…
Many children with ALL have a good outcome of their disease. After two years of chemotherapy…
A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of…